INTRODUCTION {#sec1-1}
============

Indoleamine 2, 3-dioxygenase (IDO) is an intracellular enzyme that catalyzes the transformation of L-tryptophan to *N*-formylkynurenine, which is the first and rate-controlling step in the kynurenine pathway.\[[@ref1]\] The role of IDO in immunomodulation has been reported in previous studies, including preclinical studies of allograft tolerance, inflammation, and cancer.\[[@ref2]\] Both animal and human studies have demonstrated that IDO-expressing cells function as immunosuppressors by increasing T-lymphocyte tolerance. These observations strongly suggest that IDO plays an important role in the regulation (suppression) of the adaptive immune response and thus provides an excellent therapeutic target for anticancer immunotherapy.\[[@ref3]\]

*Aloe* is a short-stemmed succulent herb what belongs to the Asphodelaceae family. The seven genera of this family include approximately 650 species.\[[@ref4]\] Of these, the 400 species of the genus *Aloe* typically grow in temperate and subtropical regions of Africa.\[[@ref5][@ref6][@ref7]\] Based on morphological characteristics,\[[@ref8]\] the genus *Aloe* has been divided into 20 subgroups, ranging from grass to tree aloes. In addition to its use in traditional medicines for the treatment of various diseases, aloe is an ingredient in many cosmetics and health foods. A previous phytochemical study revealed that the main constituents of *Aloe* are phenolic compounds, including anthraquinones, chromones, and pyrones.\[[@ref9][@ref10][@ref11]\] Aqueous *Aloe* exudates and several monomeric compounds isolated from *Aloe* exert anti-inflammatory, antioxidant, anticancer, and antidiabetic properties.\[[@ref12][@ref13][@ref15]\] However, to our knowledge, the IDO inhibitory activity of the plant has not been reported. In the present study, 18 compounds isolated from aqueous dissolved *Aloe* exudates were evaluated for their IDO inhibitory activities. Our findings have medical and pharmacological applications.

MATERIALS AND METHODS {#sec1-2}
=====================

General experimental procedures {#sec2-1}
-------------------------------

The NMR spectra were recorded using a JEOL ECA 600 spectrometer (^1^H, 600 MHz and ^13^C, 150 MHz), with tetramethylsilane as an internal standard. Heteronuclear multiple quantum correlation, heteronuclear multiple bond correlation, and ^1^H- ^1^H correlation spectroscopy spectra were recorded using a pulsed field gradient. The ESI-MS: Electrospray ionization mass spectrometry and DMSO: dimethyl sulfoxide, spectra were obtained by using an Aglient 1200 LC-MSD Trap spectrometer. Melting points were determined using an Electro thermal IA-9200 system. Column chromatography was performed using a silica gel (Kieselgel 60, 70-230, and 230-400 mesh, Merck, Darmstadt, Germany), YMC RP-18 resins, and thin layer chromatography was performed using pre-coated silica-gel 60 F~254~ and RP-18 F~254S~ plates (both 0.25 mm, Merck, Darmstadt, Germany), the spots were detected under UV light and using 10% H~2~SO~4~.

Plant material {#sec2-2}
--------------

The dried exudates of *Aloe* were purchased from herbal company, Naemome Dah, Ulsan, Korea in April 2014, and identified by Prof. Young Ho Kim, College of Pharmacy, Chungnam National University. A voucher specimen (CNU14105) was deposited at the herbarium of the College of Pharmacy, Chungnam National University in Korea.

Extraction and isolation {#sec2-3}
------------------------

The dried exudation of *Aloe* (200 g) were dissolved in H~2~O three times under ultrasonication at ambient temperature and then filtered. The filtrate was concentrated and partitioned with CHCl~3~, EtOAc, and *n*-BuOH to yield CHCl~3~ (2.0 g), EtOAc (24.0 g), and *n*-BuOH (20.0 g) fractions. The EtOAc fraction (24.0 g) was subjected to silica gel (10 × 30 cm) column chromatography with a gradient of CHCl~3~-MeOH-H~2~O (1:0:0, 30:1:0, 15:1:0, 9:1:0, 5:1:0.1, 1:1:0.1; 2.0 L for each step) to give seven fractions (Fr. E1--E7). Fraction E2 was further chromatographed on a reverse-phase (RP; 1.0 × 80 cm) column chromatography using a gradient of MeOH-H~2~O (1:4, 1:2; 500 mL each step) to give compounds 1 (37.5 mg), 10 (3.0 mg), and 11 (16.8 mg). The fraction E3 was chromatographed on an RP (1.5 × 80 cm) column with MeOH-H~2~O (1:5, 1:3.5, 1:1.5, 1:1; 800 mL each step) to obtain four subfractions (E3.1--E3.4), further purification of the subfraction E3.3 by silica gel (1.0 × 60 cm) column with CHCl~3~-MeOH (20:1, 15:1; 800 mL each step) led to compounds 4 (2.0 mg), 9 (3.0 mg), and 16 (15.0 mg). Subfraction E3.4 was separated using a silica gel (2.0 × 80 cm) column chromatography with a gradient of CHCl~3~-MeOH (15:1, 10:1; 1 L each step) to give compounds 8 (100.0 mg) and 14 (16.0 mg). Fraction E5 was column chromatographed over RP (3.0 × 80 cm), eluting with MeOH-H~2~O (1:4, 1:2, 1:1, 2:1; 1500 mL each step) to obtain five subfractions (E5.1--E5.5), then subfraction E5.3 was further chromatographed on a silica gel (1.0 × 60 cm) column chromatography with a gradient of CHCl~3~-MeOH (10:1; 800 mL) to give compound 2 (50.0 mg). Subfraction E5.5 was chromatographed on a silica gel (1.0 × 80 cm) column chromatography with CHCl~3~-MeOH-H~2~O (6.5:1:0.1; 800 mL) to yield compound 3 (100.0 mg).

The n-BuOH fraction (20.0 g) was subjected to silica gel (10.0 × 30 cm) column chromatography with a gradient of CHCl~3~-MeOH-H~2~O (15:1:0, 10:1:0, 7:1:0.1, 4:1:0.1, 2:1:0.2; 2.0 L for each step) to give six fractions (Fr. B1--B6). The fraction B3 was subjected to RP (2.5 × 60 cm) column chromatography with a gradient of acetone-MeOH-H~2~O (0.025:0.025:1, 0.1:0.1:1, 0.2:0.2:1. 0.3:0.3:1; 1.5 L for each step) to give five fractions (Fr. B3.1--B3.5). The fraction B3.2 was subjected to an silica gel (1.0 × 80 cm) column chromatography with a CHCl~3~-MeOH-H~2~O (7:1:0.1; 800 mL) to give compounds 13 (2.0 mg) and 15 (6.5 mg). The fraction B3.4 was separated using an RP (1.0 × 80 cm) column chromatography with an MeOH-H~2~O (1:2; 800 mL) elution solvent to give compound 12 (15.0 mg). The fraction B5 was subjected to RP (2.5 × 60 cm) column chromatography with a gradient of acetone-MeOH-H~2~O (0.025:0.025:1, 0.1:0.1:1, 0.2:0.2:1. 0.3:0.3:1, 0.4:0.4:1; 2.0 L for each step) to give six fractions (Fr. B5.1--B5.6). Compound 18 (20.0 mg) was isolated from fraction B5.3 using a silica gel (2.0 × 80 cm) column chromatography with CHCl~3~-MeOH-H~2~O (4:1:0.1; 1.0 L). Subfraction B5.5 was subjected to a silica gel (1.5 × 80 cm) column chromatography with a CHCl~3~-MeOH-H~2~O (5:1:0.1; 1.0 L for each step) elution solvent to give compound 17 (20.4 mg). The fraction B6 was subjected to RP (2.5 × 60 cm) column chromatography with a gradient of acetone-MeOH-H~2~O (0.025:0.025:1, 0.05:0.05:1, 0.2:0.2:1. 0.3:0.3:1, 0.4:0.4:1; 1.0 L for each step) to give seven fractions (Fr. B6.1--B6.7). Subfraction B6.5 was further purified by chromatography column over silica gel (1.0 × 80 cm) to obtain compounds 5 (15.0 mg) and 6 (3.0 mg). Compound 7 (8.0 mg) was isolated from fraction B6.7 using a silica gel (1.0 × 80 cm) column chromatography with CHCl~3~-MeOH-H~2~O (6.5:1:0.1; 800 mL).

IDO assay and determination of inhibition pattern of IDO inhibitors {#sec2-4}
-------------------------------------------------------------------

IDO assays were performed mainly as described previously by Nakano *et al*.\[[@ref16]\] Briefly, a compound serially diluted in DMSO was mixed with 1 μg of purified human IDO in an IDO assay buffer (50 mM potassium phosphate buffer, pH 6.5). Then L-(+)-ascorbic acid, methylene blue, and catalase and L-tryptophan were added to the enzyme-compound mixture to final concentrations of 50 mM, 20 mM, 10 mM, 100 μg/mL, and 200 μM, respectively. The enzyme reaction mixture was incubated at 37°C for 1 hr. After incubation, the reaction mixture was supplemented with 40 μL of 30% trichloroacetic acid and heated for 15 min at 65Β °C followed by centrifugation to remove the precipitate. The supernatant taken after centrifugation was mixed with an equal volume of Ehrlich\'s reagent (2% p-dimethylaminobenzaldehyde in acetic acid) and incubated at RT. The intensity of the color developed, which represents the concentration of L-kynurenine produced during the enzyme reaction, was measured by reading the absorbance at 480 nm wavelength.

Inhibition patterns of IDO inhibitors were determined with Lineweaver-Burk plot, for which IDO assays were run at five different L-tryptophane concentrations and four different inhibitor concentrations (0, 25, 50, 100 μL), respectively. *K*i of IDO inhibitors were calculated from the *y*-intercept of Lineweaver-Burk plot, which is denoted by (1 + \[I\]/*K*i)/V~max~.\[[@ref17][@ref18]\]

Statistical analysis {#sec2-5}
--------------------

All measurements were performed independently at least triplicate. Data were expressed as the mean ± standard deviation (SD). Statistical significance is determined by one-way analysis of variance followed by Dunnett\'s multiple comparison test, *P* \< 0.05.

RESULTS {#sec1-3}
=======

In this study, 18 compounds (1-18) were isolated from the aqueous dissolved *Aloe* exudate. The structures of compounds 1-18 were identified based on spectroscopic data, chemical evidence, and comparisons with previously reports \[[Figure 1](#F2){ref-type="fig"}\]. Their structures were elucidated as aloe emodin (1),\[[@ref19]\] aloin A (2),\[[@ref20]\] aloin B (3),\[[@ref20]\] desoxyaloin (4),\[[@ref21]\] aloinoside B (5),\[[@ref22]\] aloinoside C (6),\[[@ref23]\] aloinoside D (7),\[[@ref19]\] aloenin aglycone (8),\[[@ref24]\] feroxidin (9),\[[@ref25]\] 7-hydroxy-5-(hydroxymethyl)-2-methylchromone (10),\[[@ref24]\] 5-methylresorcinol (11),\[[@ref26]\] aloe resin D (12),\[[@ref11]\] 7-*O*-methylaloesinol (13),\[[@ref11]\] aloeresin G (14),\[[@ref27]\] *C*-2'-decoumaroylaloeresin G (15),\[[@ref14]\] 5-((*S*)-2'-oxo-4'-hydrosypentyl)-2-hydroxymethylchromone (16),\[[@ref24]\] aloveroside A (17),\[[@ref28]\] and aloenin B (18).\[[@ref28]\]

![Structures of compounds **1**--**18** from *Aloe*.](PM-13-58-g002){#F2}

The inhibitory activities of the 18 isolated compounds against IDO were evaluated. Menadione served as the positive control (IC~50~: 3.71 ± 1.26 μM). The IDO inhibition of compounds 1--18 were tested at concentration of 100 μM. At this concentration, the effects of several compounds were minimal, although compounds 1--7 showed over 60% inhibition at 100 μM. The activities of these seven compounds were examined further at lower concentrations to determine their respective IC~50~ values. Potent inhibitory activities with IC~50~ values of 46.50 ± 1.51, 40.32 ± 0.80, 42.21 ± 1.51, 44.81 ± 1.32, 43.88 ± 1.95, 39.41 ± 1.94, and 53.93 ± 0.95 μM, were determined for compounds 1--7, respectively \[[Figure 2](#F3){ref-type="fig"} and [Table 1](#T1){ref-type="table"}\].

![IDO inhibitory effects of compounds **1**--**7**, **12**, and **17**. \* Relative to that obtained in the absence of IDO inhibitor were plotted. Concentrations (μM) of inhibitors used in the experiment are as shown.](PM-13-58-g003){#F3}

###### 

The IDO inhibitory activities of compounds **1**--**18**

![](PM-13-58-g004)

An analysis of the structure-activity relationships of the isolated compounds showed that compounds 1-7 all have an anthraquinone core structure. It therefore seems likely that the anthracycline moiety is responsible at least in part for the observed inhibition of IDO.

DISCUSSION {#sec1-4}
==========

To more precisely determine the modes of inhibition of compounds 1-7, enzyme kinetics studies employing Lineweaver-Burk (double reciprocal) plots were performed. As shown in [Figure 3](#F4){ref-type="fig"}, regardless of the compound used, Lineweaver-Burk plots generated in the absence (0 μM) or presence of three different concentrations (25, 50, and 100 μM) of the respective compounds yielded almost parallel line. These results suggest that compounds 1-7 should be uncompetitive inhibitors \[[Figure 3](#F4){ref-type="fig"}\]. Based on the notion that compounds 1-7 were uncompetitive inhibitors, their inhibition constants (*K*~i~) were also calculated using the same plots \[[Table 1](#T1){ref-type="table"}\].

![The inhibition pattern of compounds **1**--**7**. Michaelis-Menten plots with data obtained in the presence (25, 50, and 100 µM, respectively) or absence of compounds **1** (A), **2** (B), **3** (C), **4** (D), **5** (E), **6** (F), and **7** (G). Lineweaver-Burk plots ^\[1^ (H), **2** (I), **3** (J), **4** (K), **5** (L), **6** (M), **7** (N)\] generated after transformation of data used in (A--G).](PM-13-58-g005){#F4}

In recent years, several studies have reported IDO inhibition by various synthetic and microbial secondary products.\[[@ref29][@ref30]\] However, studies on IDO inhibitors derived from plants are limited. To our knowledge, this is the first report detailing the IDO inhibitory activities of anthraquinone derivatives from *Aloe*. Our finding suggest that aqueous dissolved *Aloe* exudate can be used as a source of novel natural IDO inhibitors and merit testing as therapeutic agents in the treatments of cancer and immunopathologic diseases such as autoimmune, inflammatory, and allergic disorders. Moreover, the anthraquinone compounds identified in this study may be exploitable as templates for the synthesis of more potent and potentially clinical IDO inhibitors.
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